Wyeth Announces Positive Data From Phase 2 Study Of Neratinib In Advanced HER-2-Posit
 

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced data from an open-label phase 2 clinical trial of neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These data suggest that neratinib has antitumor activity in patients with advanced breast cancer positive for the ErbB-2 receptor (also known as HER-2 or Neu). These data were presented today during an oral session at the CTRC-AACR San Antonio Breast Cancer Symposium.

More...